Biotech Values

[DewDiligence]

For the record, I don’t think an ARIA valuation of $20B (your figure) is silly or even unlikely by the end of the decade; due to the magic of compounding arithmetic, a quintupling of valuation in 8 years merely requires an annual appreciation of 22%.

My main point in this thread is that you will be assuming a considerable amount of risk while seeking that 22% annual return, and this risk hadn’t been fully acknowledged by ARIA longs on this board, who have often characterized Ponatinib as a sure thing.